Policy, precision medicine, and new delivery methods dominated reader interest in 2025 on Evidence-Based Oncology (EBO), the cancer care publication of The American Journal of Managed Care.
5. How in vivo CAR T-cell therapies could rewrite the cancer care playbook
Ryan Flinn provided a comprehensive August overview of efforts to develop in vivo CAR T therapies, which generate cancer-fighting cells directly in the body. The piece covered the science and 2025 deal-making as small biotechs sought partners and financing. A late-breaking session at the American Society of Hematology on December 9 presented data on four patients with relapsed/refractory multiple myeloma treated with Kelonia Therapeutics’ investigational in vivo therapy.
4. On the path to greater precision in treating multiple myeloma
A multipart EBO cover package on multiple myeloma examined research advances timed to FDA approvals and updates from the European Hematology Association. An interview with Hearn Jay Cho, MD, PhD, of the Multiple Myeloma Research Foundation addressed sequencing among a growing array of therapies, the potential for individualized approaches using artificial intelligence, efforts to intervene earlier in disease development, and the debate over population-level screening.
3. Trump’s stance doesn’t end need for diversity in clinical trials
EBO covered the policy controversy after the administration moved to unwind certain health equity initiatives, including changes affecting research focused on historically underrepresented populations. At the FDA, legal requirements intended to ensure clinical trials reflect affected populations were left uncertain. Experts interviewed for the article argued that diverse trial enrollment improves the evidence base and benefits health care broadly.
2. Will the coming radiopharmaceutical wave reach more patients with cancer?
An April review traced scientific and commercial milestones driving interest in radiopharmaceuticals, which deliver radionuclides to targeted lesions for diagnosis and treatment. The article highlighted radioligand therapy’s role in refractory cancers and noted a major prostate cancer trial presented at the European Society for Medical Oncology that showed benefits from adding lutetium (177Lu) vipivotide tetraxetan (Pluvicto; Novartis) to androgen deprivation therapy and androgen receptor pathway inhibitors.
1. Will subcutaneous PD-1/PD-L1 inhibitors be a game changer?
Coverage of subcutaneous formulations of PD-1/PD-L1 inhibitors captured one of the year’s biggest managed care debates. Bristol Myers Squibb introduced subcutaneous nivolumab, and the FDA approved subcutaneous pembrolizumab (Keytruda; Merck) in September. Supporters cited faster delivery and patient convenience, while some clinics and experts warned of costs and implementation challenges, leaving the overall impact on access and care delivery unresolved.
Leave a Reply